Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis

Journal of the Neurological Sciences

Volumn 287, Issue 1-2, 2009, Pages 17-26

  De Santi, Lorenzo ^a   Annunziata, Pasquale ^b   Sessa, Edoardo ^a   Bramanti, Placido ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Autoimmunity; BDNF; EAE; Multiple sclerosis; Neuroinflammation; Neuroprotection; TrkB

Indexed keywords

BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLATIRAMER; K 252A; NEUROTROPHIN 3; NEUROTROPHIN 4;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SUBSTITUTION; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DNA POLYMORPHISM; DRUG MECHANISM; ENCEPHALITIS; GENE DELETION; GENE THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TISSUE REPAIR;

ANIMALS; AUTOIMMUNITY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOPROTECTION; ENCEPHALITIS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; NERVE REGENERATION; RECEPTOR, TRKB; T-LYMPHOCYTES;

EID: 70350618216     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.08.057     Document Type: Review

References (138)

1. Compston A., and Coles A. Multiple sclerosis. Lancet 372 9648 (2008) 1502-1517
2. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747
3. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., and Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 5 (1998) 278-285
4. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 252 Suppl (2005) 5v3-9
5. Bjartmar C., Wujek J.R., and Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206 2 (2003) 165-171
6. Rieckmann P., and Mäurer M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr Opin Neurol 15 3 (2002) 361-370
7. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., and Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5 1 (1999) 49-55
8. Kerschensteiner M., Stadelmann C., Dechant G., Wekerle H., and Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53 3 (2003) 292-304
9. Graber J.J., and Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther 121 2 (2009) 147-159
10. Kerschensteiner M., Gallmeier E., Behrens L., Leal V.V., Misgeld T., Klinkert W.E., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J Exp Med 189 5 (1999) 865-870
11. Stadelmann C., Kerschensteiner M., Misgeld T., Brück W., Hohlfeld R., and Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 125 Pt 1 (2002) 75-85
12. Ziemssen T., Kümpfel T., Klinkert W.E.F., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125 Pt 11 (2002) 2381-2391
13. Chen M., Valenzuela R.M., and Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 215 1-2 (2003) 37-44
14. Makar T.K., Bever C.T., Singh I.S., Royal W., Sahu S.N., Sura T.P., et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol 210 1-2 (2009) 40-51
15. Sarchielli P., Zaffaroni M., Floridi A., Greco L., Candeliere A., Mattioni A., et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler 13 3 (2007) 313-331
16. Cowan W.M. Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor. Annu Rev Neurosci (2001) 24551-24600
17. Leibrock J., Lottspeich F., Hohn A., Hofer M., Hengerer B., Masiakowski P., et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 341 6238 (1989) 149-152
18. Bauer S., Kerr B.J., and Patterson P.H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 8 3 (2007) 221-232
19. Baloh R.H., Enomoto H., Johnson E.M., and Milbrandt J. The GDNF family ligands and receptors - implications for neural development. Curr Opin Neurobiol 10 1 (2000) 103-110
20. Lindvall O., Kokaia Z., Bengzon J., Elmér E., and Kokaia M. Neurotrophins and brain insults. Trends Neurosci 17 11 (1994) 490-496
21. Seidah N.G., Benjannet S., Pareek S., Chrétien M., and Murphy R.A. Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett 379 3 (1996) 247-250
22. Martin-Zanca D., Oskam R., Mitra G., Copeland T., and Barbacid M. Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 9 1 (1989) 24-33
23. Kaplan D.R., Martin-Zanca D., and Parada L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 350 6314 (1991) 158-160
24. Klein R., Nanduri V., Jing S.A., Lamballe F., Tapley P., Bryant S., et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 66 2 (1991) 395-403
25. Arévalo J.C., and Wu S.H. Neurotrophin signaling: many exciting surprises!. Cell Mol Life Sci 63 13 (2006) 1523-1537
26. Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A., Vetuschi A., et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6 4 (2004) 347-360
27. Klein R., Conway D., Parada L.F., and Barbacid M. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell 61 4 (1990) 647-656
28. Stoilov P., Castren E., and Stamm S. Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem Biophys Res Commun 290 3 (2002) 1054-1065
29. Eide F.F., Vining E.R., Eide B.L., Zang K., Wang X.Y., and Reichardt L.F. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci 16 10 (1996) 3123-3129
30. Liepinsh E., Ilag L.L., Otting G., and Ibáñez C.F. NMR structure of the death domain of the p75 neurotrophin receptor. EMBO J 16 16 (1997) 4999-5005
31. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 25 22 (2005) 5455-5463
32. Copray S., Küst B., Emmer B., Young Lin M., Liem R., Amor S., et al. Deficient p75 low-affinity neurotrophin receptor expression exacerbates experimental allergic encephalomyelitis in C57/BL6 mice. J Neuroimmunol 148 1-2 (2004) 41-53
33. Küst B., Mantingh-Otter I., Boddeke E., and Copray S. Deficient p75 low-affinity neurotrophin receptor expression does alter the composition of cellular infiltrate in experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol 174 1-2 (2006) 92-100
34. Bayas A., Hummel V., Kallmann B.A., Karch C., Toyka K.V., and Rieckmann P. Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine 19 2 (2002) 55-58
35. Ruprecht K., Stadelmann C., Hummel V., Klein O., Brück W., and Rieckmann P. Brain derived neurotrophic factor does not act on adult human cerebral endothelial cells. Neurosci Lett 330 2 (2002) 175-178
36. Lee R., Kermani P., Teng K.K., and Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 294 5548 (2001) 1945-1948
37. Hempstead B.L. The many faces of p75NTR. Curr Opin Neurobiol 12 3 (2002) 260-267
38. Besser M., and Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162 11 (1999) 6303-6306
39. De Santi L., Cantalupo L., Tassi M., Raspadori D., Cioni C., and Annunziata P. Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis. J Neurol Sci 277 1-2 (2009) 65-70
40. Edling A.E., Nanavati T., Johnson J.M., and Tuohy V.K. Human and murine lymphocyte neurotrophin expression is confined to B cells. J Neurosci Res 77 5 (2004) 709-717
41. Yamamoto H., and Gurney M.E. Human platelets contain brain-derived neurotrophic factor. J Neurosci 10 11 (1990) 3469-3478
42. Levi-Montalcini R., Skaper S.D., Dal Toso R., Petrelli L., and Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19 11 (1996) 514-520
43. Schuhmann B., Dietrich A., Sel S., Hahn C., Klingenspor M., Lommatzsch M., et al. A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol 163 1-2 (2005) 15-23
44. Bratke K., Maruschke L., Darowski M., Kuepper M., Braun A., Virchow J.C., et al. A role for the neurotrophin receptor TrkB on maturing dendritic cells. J Neuroimmunol 189 1-2 (2007) 88-94
45. Maroder M., Bellavia D., Meco D., Napolitano M., Stigliano A., Alesse E., et al. Expression of trKB neurotrophin receptor during T cell development. Role of brain derived neurotrophic factor in immature thymocyte survival. J Immunol 157 7 (1996) 2864-2872
46. Garcia-Suarez O., Blanco-Gelaz M.A., Lopez M.L., Germana A., Cabo R., Díaz-Esnal B., et al. Massive lymphocyte apoptosis in the thymus of functionally deficient TrkB mice. J Neuroimmunol 129 1-2 (2002) 25-34
47. Berzi A., Ayata C.K., Cavalcante P., Falcone C., Candiago E., Motta T., et al. BDNF and its receptors in human myasthenic thymus: implications for cell fate in thymic pathology. J Neuroimmunol 197 2 (2008) 128-139
48. Laurenzi M.A., Barbany G., Timmusk T., Lindgren J.A., and Persson H. Expression of mRNA encoding neurotrophins and neurotrophin receptors in rat thymus, spleen tissue and immunocompetent cells. Regulation of neurotrophin-4 mRNA expression by mitogens and leukotriene B4. Eur J Biochem 223 3 (1994) 733-741
49. Lomen-Hoerth C., and Shooter E.M. Widespread neurotrophin receptor expression in the immune system and other nonneuronal rat tissues. J Neurochem 64 4 (1995) 1780-1789
50. Labouyrie E., Dubus P., Groppi A., Mahon F.X., Ferrer J., Parrens M., et al. Expression of neurotrophins and their receptors in human bone marrow. Am J Pathol 154 2 (1999) 405-415
51. Hannestad J., Levanti M.B., and Vega J.A. Distribution of neurotrophin receptors in human palatine tonsils: an immunohistochemical study. J Neuroimmunol 58 2 (1995) 131-137
52. García-Suárez O., Hannestad J., Esteban I., Martínez del Valle M., Naves F.J., and Vega J.A. Neurotrophin receptor-like protein immunoreactivity in human lymph nodes. Anat Rec 249 2 (1997) 226-232
53. Schenone A., Gill J.S., Zacharias D.A., and Windebank A.J. Expression of high- and low-affinity neurotrophin receptors on human transformed B lymphocytes. J Neuroimmunol 64 2 (1996) 141-149
54. Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., and Peeper D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430 7003 (2004) 1034-1039
55. Li Z., Beutel G., Rhein M., Meyer J., Koenecke C., Neumann T., et al. High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 113 9 (2009) 2028-2037
56. Feng X., Jiang H., Baik J.C., Edgar C., and Eide F.F. BDNF dependence in neuroblastoma. J Neurosci Res 64 4 (2001) 355-363
57. Pearse R.N., Swendeman S.L., Li Y., Rafii D., and Hempstead B.L. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 105 11 (2005) 4429-4436
58. Gravel C., Götz R., Lorrain A., and Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat Med 3 7 (1997) 765-770
59. McTigue D.M., Horner P.J., Stokes B.T., and Gage F.H. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 18 14 (1998) 5354-5365
60. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Brück W., Rauschka H., Bergmann M., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 Pt 11 (2005) 2705-2712
61. Kil K., Zang Y.C., Yang D., Markowski J., Fuoco G.S., Vendetti G.C., et al. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol 98 2 (1999) 201-207
62. Bieber A.J., Kerr S., and Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol 53 5 (2003) 680-684
63. Tobias C.A., Shumsky J.S., Shibata M., Tuszynski M.H., Fischer I., Tessler A., et al. Delayed grafting of BDNF and NT-3 producing fibroblasts into the injured spinal cord stimulates sprouting, partially rescues axotomized red nucleus neurons from loss and atrophy, and provides limited regeneration. Exp Neurol 184 1 (2003) 97-113
64. Schwartz M., Moalem G., Leibowitz-Amit R., and Cohen I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 22 7 (1999) 295-299
65. Serpe C.J., Kohm A.P., Huppenbauer C.B., Sanders V.M., and Jones K.J. Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J Neurosci 19 11 (1999) RC7
66. Novikov L., Novikova L., and Kellerth J.O. Brain-derived neurotrophic factor promotes survival and blocks nitric oxide synthase expression in adult rat spinal motoneurons after ventral root avulsion. Neurosci Lett 200 1 (1995) 45-48
67. Kishino A., Ishige Y., Tatsuno T., Nakayama C., and Noguchi H. BDNF prevents and reverses adult rat motor neuron degeneration and induces axonal outgrowth. Exp Neurol 144 2 (1997) 273-286
68. Hammarberg H., Lidman O., Lundberg C., Eltayeb S.Y., Gielen A.W., Muhallab S., et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 20 14 (2000) 5283-5291
69. Mendel I., Kerlero de Rosbo N., and Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 25 7 (1995) 1951-1959
70. Kawakami N., Odoardi F., Ziemssen T., Bradl M., Ritter T., Neuhaus O., et al. Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. J Immunol 175 1 (2005) 69-81
71. Burns J., Rosenzweig A., Zweiman B., and Lisak R.P. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 81 2 (1983) 435-440
72. Neumann H., Misgeld T., Matsumuro K., and Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci U S A 95 10 (1998) 5779-5784
73. Lisak R.P., Benjamins J.A., Bealmear B., Yao B., Land S., Nedelkoska L., et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures. Mult Scler 12 2 (2006) 149-168
74. Lisak R.P., Benjamins J.A., Bealmear B., Nedelkoska L., Yao B., Land S., et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation 4 (2007) 30
75. Kernie S.G., Liebl D.J., and Parada L.F. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19 6 (2000) 1290-1300
76. Kos C.H. Cre/loxP system for generating tissue-specific knockout mouse models. Nutr Rev 62 6 Pt 1 (2004) 243-246
77. Linker R., Lee D.-H., Siglienti I., and Gold R. Is there a role for neurotrophins in the pathology of multiple sclerosis?. J Neurol 254 Suppl 1 (2007) 33-40
78. Huang R., Huang J., Cathcart H., Smith S., and Poduslo S.E. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. J Med Genet 44 2 (2007) e66
79. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 2 (2003) 257-269
80. Bueller J.A., Aftab M., Sen S., Gomez-Hassan D., Burmeister M., and Zubieta J. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59 9 (2006) 812-815
81. Chen Z., Jing D., Bath K.G., Ieraci A., Khan T., Siao C., et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314 5796 (2006) 140-143
82. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24 45 (2004) 10099-10102
83. Neves-Pereira M., Mundo E., Muglia P., King N., Macciardi F., and Kennedy J.L. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 71 3 (2002) 651-655
84. Neves-Pereira M., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10 2 (2005) 208-212
85. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 51 1 (2002) 133-136
86. Lindquist S., Schott B.H., Ban M., Compston D.A.S., Sawcer S., and Sailer M. The BDNF-Val66Met polymorphism: implications for susceptibility to multiple sclerosis and severity of disease. J Neuroimmunol 167 1-2 (2005) 183-185
87. Blanco Y., Gómez-Choco M., Arostegui J.L., Casanova B., Martínez-Rodríguez J.E., Boscá I., et al. No association of the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) to multiple sclerosis. Neurosci Lett 396 3 (2006) 217-219
88. Zivadinov R., Weinstock-Guttman B., Benedict R., Tamaño-Blanco M., Hussein S., Abdelrahman N., et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet 16 22 (2007) 2659-2668
89. Mirowska-Guzel D., Mach A., Gromadzka G., Czlonkowski A., and Czlonkowska A. BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the Polish population. Gender differences. J Neuroimmunol 193 1-2 (2008) 170-172
90. Liguori M., Fera F., Gioia M.C., Valentino P., Manna I., Condino F., et al. Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis. Genes Brain Behav 6 2 (2007) 177-183
91. Weinstock-Guttman B., Zivadinov R., Tamaño-Blanco M., Abdelrahman N., Badgett D., Durfee J., et al. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol 188 1-2 (2007) 167-174
92. Liguori M., Fera F., Patitucci A., Manna I., Condino F., Valentino P., et al. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis. Brain Res 1256 (2009) 123-128
93. Hashimoto T., and Lewis D.A. BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 163 3 (2006) 534-537
94. Tramontina J., Frey B.N., Andreazza A.C., Zandona M., Santin A., and Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry 12 3 (2007) 230-231
95. Sarchielli P., Greco L., Stipa A., Floridi A., and Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 132 1-2 (2002) 180-188
96. Gielen A., Khademi M., Muhallab S., Olsson T., and Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol 57 5 (2003) 493-497
97. Petereit H.F., Lindemann H., and Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler 9 1 (2003) 16-20
98. Caggiula M., Batocchi A.P., Frisullo G., Angelucci F., Patanella A.K., Sancricca C., et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 62 2 (2005) 176-182
99. Pan W., Banks W.A., Fasold M.B., Bluth J., and Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37 12 (1999) 1553-1561
100. Deloire-Grassin M.S., Brochet B., Quesson B., Delalande C., Dousset V., Canioni P., et al. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci 178 1 (2000) 10-16
101. Trojano M., Pellegrini F., Fuiani A., Paolicelli D., Zipoli V., Zimatore G.B., et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61 4 (2007) 300-306
102. Goodin D.S. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 71 24 Suppl 3 (2008) S8-S13
103. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 100 24 (2003) 14157-14162
104. Aharoni R., Herschkovitz A., Eilam R., Blumberg-Hazan M., Sela M., Bruck W., et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 105 32 (2008) 11358-11363
105. Teitelbaum D., Aharoni R., Klinger E., Kreitman R., Raymond E., Malley A., et al. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Ann N Y Acad Sci 1029 (2004) 239-249
106. Comi G., Filippi M., and Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49 3 (2001) 290-297
107. Dabbert D., Rösner S., Krämer M., Schöll U., Tumani H., Mäder M., et al. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci Lett 289 3 (2000) 205-208
108. Ziemssen T., and Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 79 (2007) 537-570
109. Blanco Y., Moral E.A., Costa M., Gómez-Choco M., Torres-Peraza J.F., Alonso-Magdalena L., et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett 406 3 (2006) 270-275
110. Azoulay D., Vachapova V., Shihman B., Miler A., and Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 167 1-2 (2005) 215-218 Ott
111. Picard-Riera N., Decker L., Delarasse C., Goude K., Nait-Oumesmar B., Liblau R., et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc Natl Acad Sci U S A 99 20 (2002) 13211-13216
112. Bermel R.A., and Rudick R.A. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics 4 4 (2007) 633-646
113. Biernacki K., Antel J.P., Blain M., Narayanan S., Arnold D.L., and Prat A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 62 4 (2005) 563-568
114. Maier K., Kuhnert A.V., Taheri N., Sättler M.B., Storch M.K., Williams S.K., et al. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 169 4 (2006) 1353-1364
115. Lalive P.H., Kantengwa S., Benkhoucha M., Juillard C., and Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol 197 2 (2008) 147-151
116. Azoulay D., Mausner-Faimberg K., Urshansky N., Fahoum F., and Karni A. Interferon- therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J Neuroimmunol 211 (2009) 114-119
117. Caggiula M., Batocchi A.P., Frisullo G., Angelucci F., Patanella A.K., Sancricca C., et al. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol 118 1 (2006) 77-82
118. Hamamcioglu K., and Reder A.T. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 13 4 (2007) 459-470
119. Nibuya M., Morinobu S., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15 11 (1995) 7539-7547
120. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 11 (1983) 1444-1452
121. Zimmermann K.C., Bonzon C., and Green D.R. The machinery of programmed cell death. Pharmacol Ther 92 1 (2001) 57-70
122. Wesselborg S., Janssen O., and Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150 10 (1993) 4338-4345
123. Macchi B., Matteucci C., Nocentini U., Caltagirone C., and Mastino A. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport 10 2 (1999) 399-402
124. Zang Y.C., Kozovska M.M., Hong J., Li S., Mann S., Killian J.M., et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol 29 5 (1999) 1692-1700
125. Pender M.P. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 351 9107 (1998) 978-981
126. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res 301 1 (2000) 163-171
127. Pette M., Fujita K., Kitze B., Whitaker J.N., Albert E., Kappos L., et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40 11 (1990) 1770-1776
128. Saresella M., Marventano I., Speciale L., Ruzzante S., Trabattoni D., Della Bella S., et al. Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. J Neuroimmunol 166 1-2 (2005) 173-179
129. Okuda Y., Apatoff B.R., and Posnett D.N. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J Neuroimmunol 171 1-2 (2006) 163-170
130. Dhein J., Walczak H., Bäumler C., Debatin K.M., and Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373 6513 (1995) 438-441
131. Zipp F., Faber E., Sommer N., Müller C., Dichgans J., Krammer P.H., et al. CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. J Neuroimmunol 81 1-2 (1998) 168-172
132. Zipp F., Weller M., Calabresi P.A., Frank J.A., Bash C.N., Dichgans J., et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol 43 1 (1998) 116-120
133. Friese M.A., and Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 128 Pt 8 (2005) 1747-1763
134. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192 3 (2000) 393-404
135. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlén C., and Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194 5 (2001) 669-676
136. Perez-Pinera P., Hernandez T., García-Suárez O., de Carlos F., Germana A., Del Valle M., et al. The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. Mol Cell Biochem 295 1-2 (2007) 19-26
137. Lazarovici P., Rasouly D., Friedman L., Tabekman R., Ovadia H., and Matsuda Y. K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs. Adv Exp Med Biol 391 (1996) 367-377
138. Aharoni R., Eilam R., Domev H., Labunskay G., Sela M., and Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A 102 52 (2005) 19045-19050